L R Mehta

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Mult Scler 14:425-7. 2008
  2. doi request reprint Sporadic fatal insomnia masquerading as a paraneoplastic cerebellar syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Box 605, Rochester, NY 14642, USA
    Arch Neurol 65:971-3. 2008
  3. doi request reprint Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, University of Rochester Medical Center, 601 Elmwood Avenue, Box 605, Rochester, NY 14586, USA
    Nat Clin Pract Neurol 5:82-92. 2009
  4. doi request reprint Proof of concept studies for tissue-protective agents in multiple sclerosis
    L R Mehta
    University of Rochester Department of Neurology, Rochester, NY, USA
    Mult Scler 15:542-6. 2009
  5. pmc Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study
    K Noyes
    Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave, Box 644, Rochester, NY 14620, USA
    Neurology 77:355-63. 2011
  6. doi request reprint A randomized trial of memantine as treatment for spasticity in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 16:248-51. 2010

Detail Information

Publications6

  1. doi request reprint Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Mult Scler 14:425-7. 2008
    ....
  2. doi request reprint Sporadic fatal insomnia masquerading as a paraneoplastic cerebellar syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Box 605, Rochester, NY 14642, USA
    Arch Neurol 65:971-3. 2008
    ..Sporadic fatal insomnia is a rare prion disease that has recently been recognized...
  3. doi request reprint Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, University of Rochester Medical Center, 601 Elmwood Avenue, Box 605, Rochester, NY 14586, USA
    Nat Clin Pract Neurol 5:82-92. 2009
    ..We propose that the potential role of PUFAs as disease-modifying, anti-inflammatory treatments for MS should be revisited in proof-of-concept trials that use accepted MRI outcome measures...
  4. doi request reprint Proof of concept studies for tissue-protective agents in multiple sclerosis
    L R Mehta
    University of Rochester Department of Neurology, Rochester, NY, USA
    Mult Scler 15:542-6. 2009
    ..There is considerable interest in tissue-protective treatments for multiple sclerosis (MS)...
  5. pmc Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study
    K Noyes
    Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave, Box 644, Rochester, NY 14620, USA
    Neurology 77:355-63. 2011
    ..To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States compared to basic supportive therapy without DMT for patients with relapsing multiple sclerosis (MS)...
  6. doi request reprint A randomized trial of memantine as treatment for spasticity in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 16:248-51. 2010
    ..The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study...